Psychedelic-Assisted Therapy in Canada — The Legal and Clinical Landscape

The field of psychedelic-assisted therapy is moving fast. Five years ago, almost everything was either underground or in research trials. Today there are legal pathways for ketamine-assisted therapy in private practice, an active Special Access Program for psilocybin and MDMA in specific clinical contexts, ongoing clinical trials across multiple compounds, and a robust integration practice for clients who have engaged in non-medical contexts. The regulatory landscape is shifting again every few months.

Most of the people who reach out to me about psychedelic-assisted work are confused about what is and isn't legal, what they can and cannot access, and what role a therapist actually plays in this work. This article is a clinical and regulatory primer, written from the perspective of a practitioner with formal graduate training in the field (Vancouver Island University) currently providing preparation and integration counselling for clients in legal contexts.

A few caveats before we begin. The regulatory situation changes; please verify current details with your physician and Health Canada. Nothing in this article is medical advice or a recommendation that any specific person engage in psychedelic experiences. The field is genuinely promising and also carries real risks; thoughtful engagement is the only kind worth recommending.

What psychedelic-assisted therapy actually means

Psychedelic-assisted therapy is the use of specific psychoactive compounds, in clinical or therapeutic contexts, to support psychotherapeutic work. The compounds most frequently studied and used clinically include psilocybin (the active compound in psychedelic mushrooms), MDMA (sometimes called ecstasy in non-medical contexts), ketamine, ayahuasca and related plant medicines, and LSD. Each compound has distinctive effects, evidence bases, and risk profiles.

The frame is important: psychedelic-assisted therapy is not just taking the medicine. It is a structured therapeutic process in which the medicine is one element. Most protocols involve:

• Preparation sessions with a therapist, usually 2–4 sessions, before any medicine experience
• The medicine session itself with one or two therapists present, typically lasting 5–8 hours
• Integration sessions with a therapist, usually multiple sessions over weeks or months, after the medicine experience

The therapeutic relationship and the integration work are not optional add-ons. They are what allow the medicine to do meaningful, lasting work rather than producing a vivid experience that fades.

What is currently legal in Canada

This is the part that changes most often. As of writing, the situation is approximately:

Ketamine-assisted therapy. Ketamine, when prescribed by a physician for off-label psychiatric use, is legal in Canada. Several private clinics in BC and elsewhere offer ketamine-assisted therapy, typically requiring physician oversight, formal psychiatric assessment, and structured therapy protocols. Costs are typically not covered by public insurance.

Psilocybin and MDMA via the Special Access Program. Health Canada's Special Access Program allows physicians to apply for access to controlled substances for individual patients with serious or life-threatening conditions when conventional treatments have not worked. Some patients have accessed psilocybin and MDMA this way, though approvals are case-by-case and not common.

Clinical trials. Active clinical trials for psilocybin (depression, end-of-life anxiety, eating disorders), MDMA (PTSD), and other compounds are underway at various Canadian sites. Participation requires meeting specific clinical criteria and is competitive.

Plant medicines in religious contexts. A small number of religious organizations in Canada have legal use exemptions for ayahuasca and similar compounds. These contexts are not therapy and are not what we are discussing here.

Outside legal contexts. Many Canadians engage with psychedelics outside legal frameworks — at retreats abroad, in non-medical contexts at home, through underground therapeutic networks.

Therapists cannot facilitate these contexts. We can, however, provide preparation and integration counselling for clients who have engaged in them.

What I do at Baraka

I am clear about my scope: I provide preparation and integration counselling. I do not administer any medicine. I do not provide, prescribe, or supply any controlled substance. I do not facilitate medicine sessions outside legal frameworks.

Within that scope:

Preparation work — for clients participating in legal protocols (ketamine, clinical trial, Special Access) or for clients who have decided to engage in non-medical contexts and want to prepare thoughtfully — involves:

• Clarifying intention and what the client is actually working with
• Building therapeutic alliance and assessing readiness
• Discussing risks and contraindications honestly
• Mapping what the experience may surface and how to work with it
• Establishing integration practices in advance
• Coordinating with prescribing physicians or clinical-trial teams where applicable

Integration work — for clients returning from any psychedelic experience, in legal or non-legal contexts — involves:

• Making meaning of what happened
• Holding space for the emotional and psychological material the experience surfaced
• Working with insights, archetypal material, somatic shifts, and identity reconfigurations
• Integrating changes into daily life over time
• Addressing any difficult material that emerged

I bring depth-oriented, IFS-informed, and somatic approaches to this work, alongside formal training from Vancouver Island University's graduate certificate program in psychedelic-assisted therapy. I work in English and Farsi.

Where psychedelic-assisted therapy currently shows the most promise

The strongest clinical evidence is currently for:

MDMA-assisted therapy for PTSD. Multiple Phase 3 trials have shown substantial benefit for treatment-resistant PTSD. FDA approval in the US is anticipated; Canadian regulatory pathway is following.

Psilocybin for treatment-resistant depression. Several large trials have shown durable improvement in patients whose depression had not responded to conventional treatment.

Psilocybin for end-of-life anxiety and existential distress. Patients with terminal illness have shown significant benefit.

Ketamine for severe depression. Now widely used clinically; the strongest current real-world application.

Emerging evidence for substance use disorders, eating disorders, and complex trauma. Earlier-stage but promising.

Real risks worth naming

The field is genuinely promising and the cultural enthusiasm sometimes overshadows real risk:

• Acute psychiatric reactions during medicine sessions, particularly in clients with personal or family history of psychotic-spectrum conditions
• Persistent perceptual changes (HPPD) in a small number of users
• Re-traumatization when work is done without adequate preparation, screening, or integration
• The harm done by underqualified or boundary-violating providers in unregulated contexts (this is a real issue)
• Idealization of medicine as a quick fix when sustainable change still requires the slow work
• The integration crash, where peak experiences in medicine sessions are followed by difficult periods if integration support is inadequate

Thoughtful engagement requires holding both the promise and these risks at the same time.

The role of the integration therapist

Integration is, in my view, the part of the work that most distinguishes durable benefit from temporary inspiration. The medicine experience may show you something — a buried part of yourself, a relational pattern, a long-held grief, a different way your life could be — and integration is the work of letting that something change how you actually live.

This work happens slowly. It involves bringing the insights from the medicine experience into the small choices of daily life, into relationships, into ongoing therapy. It is the difference between I had a profound experience and I am, six months later, a meaningfully different person because of what that experience revealed.

Most of my psychedelic-integration clients work with me across many months, sometimes years. The medicine experience itself, however vivid, is one moment in a much longer arc.

When to come in

If you are considering psychedelic-assisted therapy in any context — a legal trial, a ketamine clinic, a retreat abroad, an unsanctioned setting — and want preparation support, please reach out before you engage. The preparation work substantially improves the safety and efficacy of what follows.

If you have already had a psychedelic experience and are looking for integration support, this is exactly the work I do.

Psychedelic Therapy preparation and integration at Baraka is 60 minutes at $160. Available in English and Farsi, in person at our Ambleside office and online across BC.

• Book a free 15-minute consultation with Elham → Or call (236) 455-6306 Email contact@barakaocc.com